[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.22″][et_pb_fullwidth_post_title author=”off” comments=”off” _builder_version=”3.0.89″ text_orientation=”center”][/et_pb_fullwidth_post_title][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]U.S. health regulators have ordered drugmakers to conduct clinical trials involving a total of 53,000 patients to test the safety of a controversial class of inhaled asthma drugs that are already on the market.
JeanBrownResearch.com[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row module_class=”social-share-blog” _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https://www.jbrclinicalresearch.com/wp-content/uploads/2017/12/twitter-share-1.png” align_tablet=”center” align_last_edited=”on|desktop” _builder_version=”3.23″ always_center_on_mobile=”on”][/et_pb_image][et_pb_image src=”https://www.jbrclinicalresearch.com/wp-content/uploads/2017/12/g-share-1.png” align_tablet=”center” align_last_edited=”on|desktop” _builder_version=”3.23″ always_center_on_mobile=”on”][/et_pb_image][et_pb_image src=”https://www.jbrclinicalresearch.com/wp-content/uploads/2017/12/FB-share-1.png” align_tablet=”center” align_last_edited=”on|desktop” _builder_version=”3.23″ always_center_on_mobile=”on”][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]